CE, MOC & Certificates

This three-day meeting cosponsored by the American Society of Clinical Oncology (ASCO) and the Society for the Immunotherapy of Cancer (SITC) will focus on clinical and translational research in immuno-oncology and the implications for patient care. The Symposium will address the high level of need for up-to-date information in a rapidly changing field as well as for clinical education in an area in which all aspects of care are fundamentally different from traditional therapies. Expert faculty will contextualize the latest science for clinical application, and the program will include formal opportunities for networking, discussion and interaction.

Accreditation and Designation Statement

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Society of Clinical Oncology designates this live activity for a maximum of 20.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 20.0 contact hours

All other attendees are welcome to submit a request for a Certificate of Participation, through the submission process, which may enable nonphysicians and nonpharmacists to apply their participation toward re-licensure. Please note, however, that all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.

Target Audience

This Symposium is designed for physicians and researchers involved in multidisciplinary clinical cancer care including, but not limited to medical, surgical, and radiation oncologists; pathologists; radiologists; and other translational-oriented laboratory scientists; nurses, pharmacists, advanced practice providers, and other health care professionals involved in clinical cancer care and cancer research in immuno-oncology.

Educational Needs Statement

The 2018 ASCO-SITC Clinical Immuno-Oncology Symposium builds on the success of its inaugural year in 2017 to provide an even greater clinical focus on the use of immunotherapy to treat patients with cancer.  Even as research efforts continue to swell in this area, there have also been a number of new immunotherapy-related approvals of both agents and diagnostics over the past year.  This has created a clear educational need for oncology professionals who are facing an increasing complexity in selecting and interpreting diagnostic tests, making treatment decisions, and managing the effects of those treatments. 

Learning Objectives

Upon participation in this activity, attendees will be able to

  • Demonstrate competence in describing immunological principles and the use of cellular therapy in treating patients with cancer;
  • Outline the effective use of genomics data when considering immunotherapy to inform both treatment selection and potential immune response;
  • Compare and contrast the use and effectiveness of immunotherapy in the treatment of patients with cancer in different disease sites, and how these experiences have informed clinical research and potentially led to drug approvals for immunotherapy that are not tissue specific;
  • Describe the unique considerations for clinical trial designs when testing immunotherapeutic agents, as well as the diagnostic tools and assays used to identify eligible participants;
  • Collaborate across different specialties and with all members of the oncology care team to provide effective and patient-centered treatment and supportive care for patients who are receiving immunotherapeutic agents;
  • Discuss emerging targets that are being explored for immunotherapy, new agents that are in development, and new biomarkers that could further improve treatment decisions and impact patient outcomes.

Disclaimer and Unlabeled Usage Statement

The information presented is that of the contributing faculty and presenters and does not necessarily represent the views of the Symposium Cosponsors and/or any named company or organization providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty or presenters. Therefore, before presenting any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.